An In-Depth Look at the Clinical Relevance of Pharmacogenetic Testing Ascertained
Amin Saleh Halum, Muhammad Tahir M Bhinder*, Mohammad S Shawaqfeh and Suhaib M Muflih
Nova Southeastern University, Palm Beach Gardens, Florida, USA
- Corresponding Author:
- Muhammad Tahir M Bhinder
Nova Southeastern University
11501 N. Military Trail Palm Beach Gardens
FL 33410, USA
E-mail: [email protected]
Received date: March 02, 2016; Accepted date: April 20, 2016; Published date: April 24, 2016
Citation: Halum AS, Bhinder MTM, Shawaqfeh MS, Muflih SM (2016) An In-Depth Look at the Clinical Relevance of Pharmacogenetic Testing Ascertained. J Mol Genet Med 10:210 doi:10.4172/1747-0862.1000210
Copyright: © 2016 Halum AS, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited
Background: Pharmacogenetics is the study of genetic influence on pharmacological response. Pharmacogenetic testing serves to identify the presence of genetic variants which may affect pharmacological outcomes, and allows for the selection of pharmacological therapy based on a patient's specific genetic make-up. Therefore, it has the potential to become an invaluable resource in certain fields of medicine to provide patient-tailored pharmacotherapy to patients.
Objective: To determine the clinical relevance of pharmacogenetic testing.
Methods: A systematic review was conducted from September 2013- November 2015 using the EMBASE and EBSCO host databases, identifying English language Cochrane reviews, controlled clinical trials, randomized control trials, meta-analyses and systematic reviews conducted on humans. Search terms pertaining to pharmacogenetic testing in the following medication classes: cardiovascular, oncologic, pain management, antiretroviral, and antidepressant were used. Selected articles were evaluated and assigned ratings based on the level of evidence present. A rating of "A" was assigned for high level of evidence, "B" for moderate level of evidence, and "C" for minimal level of evidence.
Results: The literature search resulted in a total of twenty-one selected articles of interest. Of these articles, seven were identified with an evidence rating of "A" and four articles with an evidence rating of "B".
Conclusion: Pharmacogenetic testing is relevant to clinical practice in certain situations. Its use provides health care providers with additional information which may enable them to treat patients more efficiently by preventing adverse reactions and anticipating therapeutic responses. A lack of prospective randomized control trials, ethical concerns, and a lack of provider knowledge pertaining to pharmacogenetic testing remain as barriers to routine pharmacogenetic testing in clinical practice. Despite these barriers, the future of pharmacogenetic testing is promising and expected to be welcomed by those whom are concerned with providing optimal pharmaceutical care.